Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis ; volume:35 ; number:8 ; day:16 ; month:7 ; year:2021 ; pages:805-820 ; date:8.2021
CNS drugs ; 35, Heft 8 (16.7.2021), 805-820, 8.2021
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-021-00834-9
- URN
-
urn:nbn:de:101:1-2021103121281678464859
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Overeem, Lucas Hendrik
- Raffaelli, Bianca
- Mecklenburg, Jasper
- Kelderman, Tim
- Neeb, Lars
- Reuter, Uwe
- SpringerLink (Online service)
Ähnliche Objekte (12)
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Episodic Migraine and Older Adults
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Episodic Migraine and Older Adults
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis